Skip to main content
SpringerLink
Log in

Reducing non-hepatic mortality in HCV increases cost effectiveness

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. US dollars

Reference

  • Leidner AJ, et al. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Applied Health Economics and Health Policy : 1 Aug 2016. Available from: URL: http://dx.doi.org/10.1007/s40258-016-0261-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reducing non-hepatic mortality in HCV increases cost effectiveness. PharmacoEcon Outcomes News 759, 26 (2016). https://doi.org/10.1007/s40274-016-3291-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3291-y

Search

Navigation